[Asia Economy Reporter Eunmo Koo] Crystal announced on the 20th that it has decided to conduct a third-party allotment paid-in capital increase worth 3,751,740,000 KRW to raise additional funds. The third-party allotment recipient is Vaximm AG, a Swiss biotech company specializing in immuno-oncology drug development.



This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing